1 minute reading time (71 words)

FDA Market Clears Erchonia’s FX 635 Laser for Chronic Low Back Pain

Erchonia Corporation announces another successful clinical trial that has resulted in the granting of an FDA 510(k) market clearance for chronic low back pain of musculoskeletal origin. This grants another first for Erchonia, which started the low-level laser category in January 2002. That year, the FDA issued its first 510(k) market clearance for any low-level laser based on Erchonia's clinical trial for chronic neck and shoulder pain.

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More